Media Coverage

KindredBio's atopic dermatitis monoclonal antibodies pique partner interest


Aug 15, 2017 - Animal Pharm
By Sian Lazell
Animal Pharm
August 15, 2017 

In a conference call regarding KindredBio's Q2 financial results, chief executive and president Richard Chin said the firm's biologics program is "generating significant interest, especially our IL-31 antibody".

KindredBio's anti-IL31 antibody is being developed for atopic dermatitis in dogs. The company has completed a pilot safety and pharmacokinetic study of anti-IL31 along with anti-IL17 and SINK – both of which are also being developed for atopic dermatitis in dogs – with results showing all molecules were well tolerated.

Chief operating officer Denise Bevers said: "It is very exciting to have clinical data for our various antibodies targeting atopic dermatitis. We plan to initiate additional pilot efficacy study shortly."

Ms Bevers also recently told Animal Pharm: "We have had a tremendous amount of interest in our antibody platform – a surprising amount, given that they are all in the pilot stage of development.

"While we did not plan to have outsourcing discussions this early, the interest has been significant enough to start a proper diligence process. We have had a number of companies conduct diligence and are anticipating some term sheets shortly. If we think the terms are worthy, we will consider partnering at this early stage; if not, we will continue development in order to realize the full value of the assets."

If KindredBio's pipeline progress remains on track, the company could become the second firm to have a mAb approved for use in the treatment of atopic dermatitis. Zoetis previously gained the first approval of an mAb therapy for atopic dermatitis in dogs in December 2016.

In a call for the firm's Q1 results, Dr Chin said: "There are only two binding epitopes on IL31 and Zoetis has IP on the other and we have IP on the other. Any other company that wants an IL31 antibody will need to come to us. We also believe our antibody is differentiated from the therapies currently on the market.

"We expect some data probably by this year because we're already starting clinical studies with our candidates. With regards to the pathway forward, we will likely partner because unlike [company's other product candidates] Mirataz and Zimeta, there isn't really competition. For a very large market against a strong competitor, it may be very helpful to have a partner.

"More importantly, there has been very high level of interest, especially given the stage of the program – almost every large veterinary company is very eager to enter the atopic dermatitis space, which is turning out to be a very large.

"As far as we know, we are the only company with the clinical stage candidate in that space. So, if the economics are attractive enough, then we may partner earlier than we had planned."

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum